Immunoprotective Effects of Surfactant Proteins in Asthma
表面活性蛋白在哮喘中的免疫保护作用
基本信息
- 批准号:7231533
- 负责人:
- 金额:$ 29.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-19 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Although pulmonary surfactant has been traditionally viewed as a surface tension reducing substance,
recent studies demonstrate that it also functions in host defense. Two surfactant proteins, SP-A and SP-D,
are members of a family of innate immune proteins known as collectins that bind pathogens and facilitate
their clearance by immune cells. SP-A and SP-D also regulate a variety of immune cell functions. The
overall hypothesis to be tested in this proposal is that SP-A and SP-D. which are synthesized and secreted
by both alveolar and airway cells, interact with cells of both the adaptive and innate immune systems to
coordinatelv maximize defense against inhaled allergens and that cause and exacerbate asthma, while
minimizing an over exuberant immune response that could result in persistent inflammation, tissue damage
and chronic lung disease. We propose to evaluate the roles of SP-A and SP-D in regulating functions of
two immune cells that play a role in asthma pathogenesis: dendritic cells and T-lymphocytes. Preliminary
studies show that SP-D enhances antigen uptake and presentation by dendritic cells, that SP-A and SP-D
inhibit lymphocyte proliferation, modulate production of regulatory and inflammatory cvtokines by dendritic
cells and that SP-A null mice have enhanced susceptibility to lung injury and allergic inflammation. Our
hypothesis is also supported by published studies showing that SP-A and SP-D inhibit allergen-induced
lymphocyte proliferation and histamine release by immune cells from asthmatic children and by studies
showing that SP-D null mice are more susceptible to allergic inflammation. Four aims are proposed. Aim 1
will determine the mechanisms by which SP-A and SP-D and their receptors, including toll like receptors
(TLRs), regulate dendritic cell function. Studies will be conducted in vitro with isolated cells and in vivo with
mice. Aim 2 will investigate the mechanism by which SP-A and SP-D regulate lymphocyte activation and
whether SP-A and SP-D directly or indirectly (via dendritic cells) affect T-cell proliferation and polarization to
a TH1 or Tn2 phenotype. Aim 3 is to investigate the role of SP-A and SP-D in the pathogenesis of
inflammatory lung disease using mouse models of asthma and chronic allergic inflammation in collectin null
mice. Aim 4 is to compare characterize levels of SP-A and SP-D in lavage fluid from asthmatics and
normals. These studies will provide information about the role of SP-A and SP-D in regulating the functions
of two important cells of the adaptive immune system and contribute to our understanding of the role of SPA
and SP-D inflammatory lung diseases. This project investigates the role of TLRs in chronic lung disease
in conjunction with Projects 2, 3 and 4. In addition, patient samples from Project 2 will be analyzed. The
project will interact with all the Cores.
尽管传统上将肺表面活性剂视为减少表面张力的物质,但
最近的研究表明,它还在宿主防御中起作用。两个表面活性剂蛋白,SP-A和SP-D,
是一个固有免疫蛋白家族的成员,称为结合病原体并促进
它们通过免疫细胞清除。 SP-A和SP-D还调节各种免疫细胞功能。这
在此提案中要检验的总体假设是SP-A和SP-D。合成和分泌的
通过牙槽和气道细胞,与适应性和先天免疫系统的细胞相互作用
坐标最大程度地防止吸入过敏原并引起哮喘,而这种情况则加重
最大程度地减少过度旺盛的免疫反应,这可能导致持续的炎症,组织损伤
和慢性肺部病。我们建议评估SP-A和SP-D在调节功能中的作用
在哮喘发病机理中起作用的两个免疫细胞:树突状细胞和T淋巴细胞。初步的
研究表明,SP-D增强了树突状细胞的抗原摄取和表现,SP-A和SP-D
抑制淋巴细胞增殖,通过树突状调节调节性和炎症性CVTOKINE的产生
细胞和SP-A NULL小鼠对肺损伤和过敏性炎症具有增强的敏感性。我们的
已发表的研究表明,SP-A和SP-D抑制过敏原诱导的,也支持假设
免疫细胞从哮喘儿童和研究
表明SP-D NULL小鼠更容易受到过敏性炎症的影响。提出了四个目标。目标1
将确定SP-A和SP-D及其受体的机制,包括Toll类似于受体
(TLR),调节树突状细胞功能。研究将在体外与分离的细胞和体内进行体外进行
老鼠。 AIM 2将研究SP-A和SP-D调节淋巴细胞激活和的机制
SP-A和SP-D是直接或间接(通过树突细胞)影响T细胞增殖和极化
TH1或TN2表型。目的3是研究SP-A和SP-D在发病机理中的作用
使用哮喘和慢性过敏性炎症的小鼠模型炎症性肺部疾病
老鼠。 AIM 4是比较哮喘患者的灌洗液中SP-A和SP-D的特征
正常。这些研究将提供有关SP-A和SP-D在调节功能中的作用的信息
自适应免疫系统的两个重要细胞,并有助于我们理解水疗中心的作用
和SP-D炎性肺部疾病。该项目调查了TLR在慢性肺病中的作用
与项目2、3和4结合使用。此外,将分析项目2的患者样本。这
项目将与所有核心互动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JO RAE WRIGHT其他文献
JO RAE WRIGHT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JO RAE WRIGHT', 18)}}的其他基金
SP-A Regulation of Host Response in Asthma and Allergic Inflammation
SP-A 调节哮喘和过敏性炎症中的宿主反应
- 批准号:
8325217 - 财政年份:2009
- 资助金额:
$ 29.55万 - 项目类别:
Immunoprotective Effects of Surfactant Proteins in Asthma
表面活性蛋白在哮喘中的免疫保护作用
- 批准号:
7917407 - 财政年份:2009
- 资助金额:
$ 29.55万 - 项目类别:
Research Core 2: Pulmonary Biology and Disease
研究核心 2:肺部生物学与疾病
- 批准号:
6741112 - 财政年份:2004
- 资助金额:
$ 29.55万 - 项目类别:
Role of Surfactant in Innate and Adaptive Immunity
表面活性剂在先天性和适应性免疫中的作用
- 批准号:
6365341 - 财政年份:2001
- 资助金额:
$ 29.55万 - 项目类别:
相似海外基金
Expecting Mothers' Study of Consumption or Avoidance of Peanut and Egg (ESCAPE)
准妈妈食用或避免花生和鸡蛋的研究(ESCAPE)
- 批准号:
10733927 - 财政年份:2023
- 资助金额:
$ 29.55万 - 项目类别:
Metabolic perturbations in conventional dendritic cells modulate Tfh13 induction in asthmatic sensitization
传统树突状细胞的代谢扰动调节哮喘致敏中的 Tfh13 诱导
- 批准号:
10587341 - 财政年份:2022
- 资助金额:
$ 29.55万 - 项目类别:
Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
- 批准号:
10563192 - 财政年份:2022
- 资助金额:
$ 29.55万 - 项目类别:
Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
- 批准号:
10418189 - 财政年份:2022
- 资助金额:
$ 29.55万 - 项目类别:
Perforin 2 controls unconventional cytokine release from mucosal APC
穿孔素 2 控制粘膜 APC 的非常规细胞因子释放
- 批准号:
10629434 - 财政年份:2021
- 资助金额:
$ 29.55万 - 项目类别: